Open AccessSIRT1: A promising therapeutic target for chronic pain
Author(s) -
Song FanHe,
Liu DaiQiang,
Zhou YaQun,
Mei Wei
Publication year - 2022
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/cns.13838
Subject(s) - medicine , chronic pain , inflammation , peripheral neuropathy , spinal cord injury , neuropathic pain , oxidative stress , sirtuin 1 , bioinformatics , spinal cord , pharmacology , physical therapy , diabetes mellitus , downregulation and upregulation , endocrinology , biochemistry , chemistry , gene , psychiatry , biology
Chronic pain remains an unresolved problem. Current treatments have limited efficacy. Thus, novel therapeutic targets are urgently required for the development of more effective analgesics. An increasing number of studies have proved that sirtuin 1 (SIRT1) agonists can relieve chronic pain. In this review, we summarize recent progress in understanding the roles and mechanisms of SIRT1 in mediating chronic pain associated with peripheral nerve injury, chemotherapy‐induced peripheral neuropathy, spinal cord injury, bone cancer, and complete Freund's adjuvant injection. Emerging studies have indicated that SIRT1 activation may exert positive effects on chronic pain relief by regulating inflammation, oxidative stress, and mitochondrial dysfunction. Therefore, SIRT1 agonists may serve as potential therapeutic drugs for chronic pain.